Sensei Biotherapeutics, Inc. (SNSE) — SEC Filings
Sensei Biotherapeutics, Inc. (SNSE) — 40 SEC filings. Latest: 8-K (Mar 30, 2026). Includes 29 8-K, 5 10-Q, 2 DEF 14A.
View Sensei Biotherapeutics, Inc. on SEC EDGAR
Overview
Sensei Biotherapeutics, Inc. (SNSE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 30, 2026: Sensei Biotherapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits, with the primary document being an iXBRL 8-K.
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Sensei Biotherapeutics, Inc. is neutral.
Filing Type Overview
Sensei Biotherapeutics, Inc. (SNSE) has filed 29 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of SNSE's 38 recent filings, 4 were flagged as high-risk, 15 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$10.5M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $70.5M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. John F. McDonald
- Dr. Michael J. Ybarra
- John W. Sarles, Jr.
- Ms. Jennifer L. Jones
- Dr. Jonathan Jonathan
- Jessie English
- James Peyer
- Thomas Ricks
- Dr. Robert L. Kirk
- John W. McDonald
- Dr. John W. Miller
Industry Context
Sensei Biotherapeutics operates in the highly competitive and rapidly evolving biopharmaceutical sector, specifically focusing on developing novel immunotherapies. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Companies like Sensei are often valued based on the potential of their pipeline and platform technologies rather than current revenue.
Top Tags
financial-reporting (6) · financials (6) · corporate-governance (5) · management-change (4) · operations (4) · filing (4) · 10-Q (4) · 8-k (3) · Biotechnology (3) · delisting (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-39980 | Identifies the company's filing with the SEC. |
| ZIP Code | 20850 | Part of the company's principal executive office address. |
| Revenue | $0 | No revenue for Q2 2025 and YTD 2025, consistent with clinical-stage status. |
| Net Loss (Q2 2025) | $10.5M | Decreased from $13.2 million in Q2 2024, showing improved cost control. |
| Net Loss (YTD 2025) | $21.5M | Decreased from $27.0 million in YTD 2024, reflecting overall expense reductions. |
| R&D Expense (Q2 2025) | $7.1M | Reduced from $9.4 million in Q2 2024, indicating a more focused R&D strategy. |
| R&D Expense (YTD 2025) | $14.7M | Reduced from $19.1 million in YTD 2024, a significant cut in development spending. |
| G&A Expense (Q2 2025) | $3.4M | Reduced from $3.8 million in Q2 2024, showing administrative cost efficiencies. |
| Personnel Restructuring Costs (Q2 2025) | $0.2M | Incurred due to ongoing efforts to optimize workforce. |
| Cash and Marketable Securities | $70.5M | As of June 30, 2025, down from $89.0 million at December 31, 2024, highlighting cash burn. |
| Cash Burn (YTD 2025) | $18.5M | Represents the decrease in cash and marketable securities over six months. |
| Reporting Period End Date | 20250331 | Indicates the specific quarter the financial data pertains to. |
| Filing Date | 20250506 | Shows when the company submitted its quarterly report to the SEC. |
| Prior Year Q1 End Date | 2024-03-31 | Provides a comparative point for year-over-year analysis. |
| Prior Year End Date | 2024-12-31 | Used for comparing year-end financial positions. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Sensei Biotherapeutics, Inc. (SNSE)?
Sensei Biotherapeutics, Inc. has 40 recent SEC filings from Jan 2024 to Mar 2026, including 29 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SNSE filings?
Across 40 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 35 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Sensei Biotherapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sensei Biotherapeutics, Inc. (SNSE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sensei Biotherapeutics, Inc.?
Key financial highlights from Sensei Biotherapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SNSE?
The investment thesis for SNSE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sensei Biotherapeutics, Inc.?
Key executives identified across Sensei Biotherapeutics, Inc.'s filings include Dr. John F. McDonald, Dr. Michael J. Ybarra, John W. Sarles, Jr., Ms. Jennifer L. Jones, Dr. Jonathan Jonathan and 6 others.
What are the main risk factors for Sensei Biotherapeutics, Inc. stock?
Of SNSE's 38 assessed filings, 4 were flagged high-risk, 15 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Sensei Biotherapeutics, Inc.?
Forward guidance and predictions for Sensei Biotherapeutics, Inc. are extracted from SEC filings as they are enriched.